It is essential for healthcare and pharmaceutical companies to be aware of both critical and non-critical risks when conducting quality clinical trials. However, managing both takes time and money -- resources that clinical teams are often strapped for. Additionally, the risks that organisations define at the start of the trial may change, meaning the data they need to collect will also change. In order to address these challenges, researchers must break down silos and create a centralised process for monitoring and managing risk. Many organisations are turning to risk-based quality management (RBQM) practices to make that happen.